




# Essai Clinique

Généré le 27 avr. 2025 à partir de

Titre	A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Protocole ID	TROPION-Breast04
ClinicalTrials.gov ID	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06112379">NCT06112379</a>
Type(s) de cancer	Sein
Phase	Phase III
Type étude	Clinique
Médicament	Datopotamab deruxtecan en néoadjuvant + durvalumab suivi de durvalumab en adjuvant avec ou sans chimiothérapie versus pembrolizumab en néoadjuvant + chimiothérapie suivi de pembrolizumab en adjuvant avec ou sans chimiothérapie
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL  PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	
Investigateur principal	Dr Jonathan Noujaim
Coordonnateur	Audrey Lamoureux 514-252-3400 poste 6258
Statut	Actif en recrutement
But étude	This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Critères d'éligibilité	<ul style="list-style-type: none"><li>• Participant must be <math>\geq 18</math> years, at the time of signing the ICF.</li><li>• Histologically confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/HER2-negative breast cancer</li><li>• ECOG PS of 0 or 1</li><li>• Provision of acceptable tumor sample</li><li>• Adequate bone marrow reserve and organ function</li><li>• Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.</li></ul>
Critères d'exclusion	<ul style="list-style-type: none"><li>• History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before randomization and of low potential risk for recurrence.</li><li>• Evidence of distant disease.</li><li>• Clinically significant corneal disease.</li><li>• Has active or uncontrolled hepatitis B or C virus infection.</li><li>• Known HIV infection that is not well controlled.</li><li>• Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections.</li><li>• Known to have active tuberculosis infection</li><li>• Resting ECG with clinically significant abnormal findings.</li><li>• Uncontrolled or significant cardiac disease.</li></ul>

- History of non-infectious ILD/pneumonitis
- Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer
- For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant.
- Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer.